Chaperones News and Research

RSS

HSF1A stimulates more protein chaperones and reduces protein misfolding

Scientists at Duke University Medical Center have found some compounds that improve a cell's ability to properly "fold" proteins and could lead to promising drugs for degenerative nerve diseases, including Huntington's disease, Alzheimer's disease and Parkinson's disease.

20 Jan 2010

Amicus Therapeutics presents corporate outlook for 2010 at Annual J.P. Morgan Healthcare Conference

Amicus Therapeutics today outlined the Company's three key strategic priorities and presented a corporate outlook for 2010 at the 28th Annual J.P. Morgan Healthcare Conference.

12 Jan 2010

Scientists discover new molecular protein that protects bacteria from stomach acid

Just like teenagers at a prom, proteins are tended by chaperones whose job it is to prevent unwanted interactions among immature clients. And at the molecular level, just as at the high school gym level, it's a job that usually requires a lot of energy.

29 Dec 2009

Copper sequestering drug tetrathiomolybdate shown to be effective in treating Wilson disease

The copper sequestering drug tetrathiomolybdate (TM) has been shown in studies to be effective in the treatment of Wilson disease, a disease caused by an overload of copper, and certain metastatic cancers.

27 Nov 2009

Shire announces third quarter 2009 financial results

Shire plc, the global specialty biopharmaceutical company, announces results for the three months to September 30, 2009.

31 Oct 2009

CytRx study reveals potential of molecular chaperones in design of anti-aging pharmaceuticals

CytRx Corporation, a biopharmaceutical company and a leader in molecular chaperone regulation technology, today announced that a paper published in the peer-reviewed journal Gerontology concluded that molecular chaperone amplification may represent a “significant strategy” in the future design of anti-aging pharmaceuticals.

29 Oct 2009

CytRx granted patent for molecular chaperone amplifier drug candidate

CytRx Corporation, a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that it has been granted a key patent by the European Patent Office that covers through 2024 the use of its orally available molecular chaperone amplifier drug candidate arimoclomol for the treatment or prevention of neurodegenerative diseases of the central nervous system (CNS).

10 Sep 2009

Cytrx to submit revised protocol for arimoclomol Phase IIb clinical trial

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced its intention during the 2009 fourth quarter to submit a revised protocol for its planned Phase IIb clinical trial for arimoclomol as a treatment for amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). The decision follows receipt of an anticipated written letter from the U.S.

8 Sep 2009

Heat shock proteins provide protection against cataracts

The human eye lens consists of a highly concentrated mix of several proteins. Protective proteins prevent these proteins from aggregating and clumping. If this protective function fails, the lens blurs and the patient develops cataracts. Two research groups at the Department of Chemistry of the Technische Universitaet Muenchen (TUM) have succeeded in explaining the molecular architecture of this kind of protective protein.

31 Jul 2009

Innovative partnership targets cancer-causing 'chaperones'

Cancer Research Technology (CRT) and The Institute of Cancer Research (ICR) today announced a major research collaboration with AstraZeneca. The three partners will combine their expertise to discover and develop potential new anti-cancer drugs to target molecular "chaperones" which support the growth of cancer cells.

10 Jun 2009

Drugs designed to tackle endoplasmic reticulum stress might be useful in treating heart disease

Researchers say they have evidence to explain what separates your average blood vessel plaque from those that are at high risk for triggering the development of dangerous - even fatal - blood clots.

5 May 2009

Researchers give mutants another chance

Researchers at Fox Chase Cancer Center have demonstrated that it might be possible to treat genetic diseases, including some forms of cancer, by "rescuing" the misshapen, useless proteins produced by some mutant genes.

11 Feb 2009

Fat busting drug Leptin could make a comeback

When an obesity drug called Leptin was first discovered by scientists 13 years ago, experts hoped the appetite-suppressing hormone would be a possible cure for obesity.

7 Jan 2009

New hope for leptin as a solution to obesity

The discovery more than a decade ago of leptin, an appetite-suppressing hormone secreted by fat tissue, generated headlines and great hopes for an effective treatment for obesity.

6 Jan 2009

Novel treatment option for obesity

A new study in the January 7th issue of Cell Metabolism , a Cell Press publication, helps to explain why obese people and animals fail to respond to leptin, a hormone produced by fat that signals the brain to stop eating.

6 Jan 2009

How household bleach kills bacteria

Despite the fact that household bleach is commonly used as a disinfectant, exactly how it works to fight bacteria remained an open question.

16 Nov 2008

Researchers aim to over-stress already taxed mantle cell lymphoma cells

Cancer cells are already stressed by the fast pace they require to grow and spread and scientists believe a little more stress just may kill them.

11 Nov 2008

CytRx to present new data on molecular chaperone drug discovery technology

CytRx Corporation today announced that Bin Zhang, Ph.D., Associate Director of Biochemistry and Screening, will present at the monthly meeting of the San Diego "LEADS" discussion group, the premium San Diego consortium of screening researchers, to be held on October 1, 2008.

25 Sep 2008

Therapies which boost the clearance of faulty proteins in cells may slow down ageing

Scientists say as people age, their cells become less efficient at getting rid of damaged protein and the result is a buildup of toxic material; this is particularly apparent in Alzheimer's, Parkinson's disease and other neurodegenerative disorders associated with ageing.

11 Aug 2008

Scientists stop age-related decline in an entire organ

As people age, their cells become less efficient at getting rid of damaged protein - resulting in a buildup of toxic material that is especially pronounced in Alzheimer's, Parkinson's disease, and other neurodegenerative disorders.

10 Aug 2008